Equities Analysts Set Expectations for Liquidia Q2 Earnings

Liquidia Co. (NASDAQ:LQDA) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Liquidia in a research report issued on Thursday, March 20th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

A number of other brokerages have also recently issued reports on LQDA. Needham & Company LLC lifted their target price on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Scotiabank raised their target price on shares of Liquidia from $30.00 to $34.00 and gave the stock a “sector outperform” rating in a report on Thursday. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Stock Performance

Liquidia stock opened at $15.44 on Friday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -9.47 and a beta of 0.07. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.99. The firm’s 50 day moving average price is $14.73 and its two-hundred day moving average price is $12.14.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million.

Institutional Trading of Liquidia

Several large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets raised its position in shares of Liquidia by 735.1% in the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after purchasing an additional 123,402 shares during the period. Barclays PLC lifted its position in shares of Liquidia by 265.0% during the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after purchasing an additional 72,591 shares during the last quarter. Whitefort Capital Management LP grew its holdings in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after buying an additional 927,546 shares during the last quarter. JPMorgan Chase & Co. increased its position in Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after buying an additional 210,753 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after buying an additional 230,820 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In other news, CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. The trade was a 2.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,445 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $13.00, for a total value of $31,785.00. Following the completion of the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. This represents a 0.90 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,245 shares of company stock valued at $843,326. Corporate insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).